The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Abstract
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is associated with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other breast cancer subtypes. This is observed despite its usual high sensitivity to chemotherapy. In the advanced setting, responses observed with chemotherapy lack durability. Early-stage clinical studies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given for the treatment of advanced TNBC with BRCA gene dysfunction. The molecular complexity of TNBC has led to proposed subclassifications, which will be of great value for the development of targeted therapies. In this review, we discuss the biology of TNBC at the pathologic and the molecular levels. We also elaborate on the role of systemic therapies and the results of the first phase III clinical trial evaluating the addition of iniparib, a novel investigational anticancer agent that does not possess characteristics typical of the PARP inhibitor class, in combination with chemotherapy in advanced TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationGenome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationPaclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationMetastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Self-citationBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Self-citationkConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492
The molecular portraits of breast tumors are conserved across microarray platforms
Hu, Z., Fan, C., Oh, D. S., Marron, J., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-96 · Cited by 1,491
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Self-citationAmé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., & Sotiriou, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4756 · Cited by 828
Self-citationIniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M., Campone, M., Brain, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 623
Kreike, B., van Kouwenhove, M., Horlings, H., Weigelt, B., Peterse, H., Bartelink, H., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611
Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., Schwartz, G. F., Park, P. K., Rosenberg, A. L., Brill, K., et al. (2007) · Cancer · doi:10.1002/cncr.22836 · Cited by 602
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 602
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Self-citationGonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Weigelt, B., Horlings, H., Kreike, B., Hayes, M., Hauptmann, M., Wessels, L., de Jong, D., Van de Vijver, M., Veer, L. V., & Peterse, J. (2008) · The Journal of Pathology · doi:10.1002/path.2407 · Cited by 562
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516
Teschendorff, A. E., Miremadi, A., Pinder, S. E., Ellis, I. O., & Caldas, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r157 · Cited by 497
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
Brufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 421
De Laurentiis, M., Cancello, G., D'Agostino, D., Giuliano, M., Giordano, A., Montagna, E., Lauria, R., Forestieri, V., Esposito, A., Silvestro, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3787 · Cited by 416
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390
Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354
Fulford, L. G., Easton, D. F., Reis‐Filho, J. S., Sofronis, A., Gillett, C. E., Lakhani, S. R., & Hanby, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02453.x · Cited by 352
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
Rodríguez-Pinilla, S. M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., & Palacios, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2281 · Cited by 324
Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers
Bertucci, F., Finetti, P., Cervera, N., Charafe-Jauffret, E., Mamessier, E., Adélaïde, J., Debono, S., Houvenaeghel, G., Maraninchi, D., Viens, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0031 · Cited by 310
Fulford, L. G., Reis-Filho, J. S., Ryder, K., Jones, C., Gillett, C. E., Hanby, A., Easton, D., & Lakhani, S. R. (2007) · Breast Cancer Research · doi:10.1186/bcr1636 · Cited by 306
B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
Moyano, J. V. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25888 · Cited by 272
Anders, C. K., Fan, C., Parker, J. S., Carey, L. A., Blackwell, K. L., Klauber-DeMore, N., & Perou, C. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9199 · Cited by 263
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Calza, S., Hall, P., Auer, G., Bjöhle, J., Klaar, S., Kronenwett, U., Liu, E. T., Miller, L., Ploner, A., Smeds, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1517 · Cited by 262
Triple-negative breast cancers are increased in black women regardless of age or body mass index
Stead, L. A., Lash, T. L., Sobieraj, J. E., Chi, D. D., Westrup, J. L., Charlot, M., Blanchard, R. A., Lee, J. C., King, T. C., & Rosenberg, C. L. (2009) · Breast Cancer Research · doi:10.1186/bcr2242 · Cited by 250
O'Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Rugo, H. S., Miller, K., Yardley, D. A., Carlson, R. W., Finn, R. S., Charpentier, E., Freese, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1007 · Cited by 245
Synthetic Lethality — A New Direction in Cancer-Drug Development
Iglehart, J. D., & Silver, D. P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0903044 · Cited by 232
Rice, J. C., Ozcelik, H., Maxeiner, P., Andrulis, I., & Futscher, B. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.9.1761 · Cited by 229
Mammary development meets cancer genomics
Prat, A., & Perou, C. M. (2009) · Nature Medicine · doi:10.1038/nm0809-842 · Cited by 213
Yau, C., Esserman, L., Moore, D. H., Waldman, F., Sninsky, J., & Benz, C. C. (2010) · Breast Cancer Research · doi:10.1186/bcr2753 · Cited by 212
Typical medullary breast carcinomas have a basal/myoepithelial phenotype
Jacquemier, J., Padovani, L., Rabayrol, L., Lakhani, S. R., Penault‐Llorca, F., Denoux, Y., Fiche, M., Figueiro, P., Maisongrosse, V., Ledoussal, V., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1845 · Cited by 202
Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., Cornelissen, S., Holtkamp, M., Froklage, F. E., de Vries, E. G. E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq624 · Cited by 200
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors
Laakso, M., Loman, N., Borg, Å., & Isola, J. (2005) · Modern Pathology · doi:10.1038/modpathol.3800456 · Cited by 190
Viale, G., Rotmensz, N., Maisonneuve, P., Bottiglieri, L., Montagna, E., Luini, A., Veronesi, P., Intra, M., Torrisi, R., Cardillo, A., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0206-z · Cited by 190
Self-citationMultifactorial Approach to Predicting Resistance to Anthracyclines
Desmedt, C., Di Leo, A., de Azambuja, E., Larsimont, D., Haibe-Kains, B., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.-P., Carly, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2231 · Cited by 181
Self-citationRakha, E. A., El‐Sayed, M. E., Green, A. R., Paish, E. C., Lee, A. H. S., & Ellis, I. O. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02638.x · Cited by 169
Treatment of HER2-overexpressing breast cancer
Baselga, J. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq421 · Cited by 166
Self-citationCarey, L. A., Rugo, H. S., Marcom, P. K., Irvin, W., Ferraro, M., Burrows, E., He, X., Perou, C. M., & Winer, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1009 · Cited by 163
Targeting the DNA Damage Response in Cancer
Ljungman, M. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163
Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer
Arnes, J. B., Brunet, J.-S., Stefansson, I., Bégin, L. R., Wong, N., Chappuis, P. O., Akslen, L. A., & Foulkes, W. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2064 · Cited by 158
Isakoff, S. J., Overmoyer, B. A., Tung, N., Gelman, R. S., Giranda, V. L., Bernhard, K. M., Habin, K. R., Ellisen, L. W., Winer, E. P., & Goss, P. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1019 · Cited by 152
Robert, N. J., Dieras, V. C., Glaspy, J. A., Brufsky, A., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Zhou, X., & Phan, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.1005 · Cited by 140
Magdinier, F., Ribieras, S., Lenoir, G., Frappart, L., & Dante, R. (1998) · Oncogene · doi:10.1038/sj.onc.1202248 · Cited by 134
Jumppanen, M., Gruvberger-Saal, S. K., Kauraniemi, P., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1649 · Cited by 132
Gucalp, A., & Traina, T. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181ce4ae1 · Cited by 131
Yu, K., Lee, C. H., Tan, P. H., & Tan, P. B. O. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0085 · Cited by 124
Treszezamsky, A. D., Kachnic, L. A., Feng, Z., Zhang, J., Tokadjian, C., & Powell, S. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0601 · Cited by 113
Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer
Potemski, P., Kusińska, R., Watała, C. W., Płuciennik, E., Bednarek, A. K., & Kordek, R. (2005) · Oncology · doi:10.1159/000090986 · Cited by 102
DePinho, R. A., & Polyak, K. (2004) · Nature Genetics · doi:10.1038/ng0904-932 · Cited by 91
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Perez, E. A., Patel, T., & Moreno‐Aspitia, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0824-0 · Cited by 90
Rodriguez, A. A., Makris, A., Wu, M.-F., Rimawi, M. F., Froehlich, A. M., Dave, B., Hilsenbeck, S. G., Chamness, G. C., Lewis, M. T., Dobrolecki, L. E., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0983-z · Cited by 79
Brufsky, A., Bondarenko, I., Smirnov, V., Hurvitz, S. A., Perez, E. A., Ponomarova, O. V., Vynnychenko, I. O., Swamy, R., Mu, H., & Rivera, R. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-42 · Cited by 67
Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype
Rodríguez-Pinilla, S. M., Rodríguez‐Gil, Y., Moreno‐Bueno, G., Sarrió, D., Martín-Guijarro, M. D. C., Hernández, L., & Palacios, J. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213427.84245.92 · Cited by 64
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Ihemelandu, C. U., Leffall, L. D., DeWitty, R. L., Naab, T. J., Mezghebe, H. M., Makambi, K. H., Adams-Campbell, L. L., & Frederick, W. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9477-6 · Cited by 44
Moinfar, F. (2008) · Pathobiology · doi:10.1159/000123850 · Cited by 38
Bhattacharyya, G. S., Basu, S., Agarwal, V., Malhotra, H., Pareekh, P., Babu, K. G., & Aggarwala, D. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72076-2 · Cited by 23
Salama, P. R., Platell, C. F. E., & Iacopetta, B. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2439 · Cited by 14
Wang, Z., Hu, X., Chen, L., Wang, J., Wang, H., Wang, L., Liu, G., Hu, Z., Wu, J., & Zhimin, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1100 · Cited by 10
Ossovskaya, V., Lim, C.-U., Schools, G. P., Kalurupalle, S., Roninson, I. B., & Broude, E. V. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-p5-06-09 · Cited by 7
Rody, A., Karn, T., Liedtke, C., Pusztai, L., Ruckhäberle, E., Hanker, L., Gaetje, R., Solbach, C., Ahr, A., Metzler, D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.sabcs10-s5-5 · Cited by 5
Cited by
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Self-citationEccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Self-citation
Metadata
- Authors
- Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., Di Leo, A., Baselga, J., Sotiriou, C., & Piccart-Gebhart, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-20
- Volume
- 30
- Issue
- 15
- Pages
- 1879-1887
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145896038
- Cited by
- 465
- References
- 107
- FWCI
- 13.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.